SEDAR-SEMICYUC consensus on the management of haemostasis disorders in severe COVID-19 patients
J V Llau 1 , R Ferrandis 2 , P Sierra 3 , F Hidalgo 4 , C Cassinello 5 , A Gómez-Luque 6 , M Quintana 7 , R Amezaga 8 , M Geroi 9 , A Serrano 10 , P Marcos 11
Infection due to the SARS-CoV-2 coronavirus, which causes COVID-19, tends to predispose patients to hypercoagulability, with an increased risk of thrombotic disease of a multifactor origin. In view of the need to establish a series of recommendations for the management of coagulation disorders in severe COVID-19 patients, the working groups of the Spanish Society of Anesthesia-Resuscitation and Pain Therapy (Sociedad Española de Anestesiología-Reanimación y Terapéutica del Dolor [SEDAR]) and the Spanish Society of Intensive and Critical Care Medicine and Coronary Units (Sociedad Española de Medicina Intensiva, Crítica y Unidades Coronarias [SEMICYUC]) decided to join our forces and knowledge and develop a consensus document with the aim of providing guidelines for dealing with these patients.
As the result of intense work, with the posterior participation of review committees from both Societies, a manuscript was developed that has just been published by the Revista Española de Anestesiología y Reanimación (REDAR).1 For different reasons unrelated to the authors, joint and simultaneous publication in Medicina Intensiva has not been possible.